[go: up one dir, main page]

WO1997037966B1 - Cytofectines quaternaires - Google Patents

Cytofectines quaternaires

Info

Publication number
WO1997037966B1
WO1997037966B1 PCT/US1997/005757 US9705757W WO9737966B1 WO 1997037966 B1 WO1997037966 B1 WO 1997037966B1 US 9705757 W US9705757 W US 9705757W WO 9737966 B1 WO9737966 B1 WO 9737966B1
Authority
WO
WIPO (PCT)
Prior art keywords
groups
absent
compound according
heteroatoms
acyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1997/005757
Other languages
English (en)
Other versions
WO1997037966A1 (fr
Filing date
Publication date
Priority claimed from US08/629,965 external-priority patent/US5994317A/en
Application filed filed Critical
Priority to EP97920200A priority Critical patent/EP0902780B1/fr
Priority to JP53642397A priority patent/JP4031045B2/ja
Priority to DE69707870T priority patent/DE69707870T2/de
Priority to AT97920200T priority patent/ATE207874T1/de
Priority to CA002251169A priority patent/CA2251169C/fr
Priority to DK97920200T priority patent/DK0902780T3/da
Publication of WO1997037966A1 publication Critical patent/WO1997037966A1/fr
Publication of WO1997037966B1 publication Critical patent/WO1997037966B1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Abstract

Cette invention concerne des lipides cationiques possédant un groupe tête d'ammonium quaternaire dérivé qui améliorent la capacité de ciblage de cellules et l'efficacité transgénique pour apporter des molécules dans des cellules. Les lipides comprennent une séquence de liaison comportant des groupes fonctionnels qui servent de sites pour la fixation d'autres substances thérapeutiques, d'autres ligands de récepteur cellulaire ou d'autres agents bioactifs.
PCT/US1997/005757 1996-04-09 1997-04-08 Cytofectines quaternaires Ceased WO1997037966A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP97920200A EP0902780B1 (fr) 1996-04-09 1997-04-08 Cytofectines quaternaires
JP53642397A JP4031045B2 (ja) 1996-04-09 1997-04-08 四級サイトフェクチン
DE69707870T DE69707870T2 (de) 1996-04-09 1997-04-08 Quartäre cytofectine
AT97920200T ATE207874T1 (de) 1996-04-09 1997-04-08 Quartäre cytofectine
CA002251169A CA2251169C (fr) 1996-04-09 1997-04-08 Cytofectines quaternaires
DK97920200T DK0902780T3 (da) 1996-04-09 1997-04-08 Kvaternære cytofectiner

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/629,965 US5994317A (en) 1996-04-09 1996-04-09 Quaternary cytofectins
US08/629,965 1996-04-09

Publications (2)

Publication Number Publication Date
WO1997037966A1 WO1997037966A1 (fr) 1997-10-16
WO1997037966B1 true WO1997037966B1 (fr) 1997-11-13

Family

ID=24525211

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/005757 Ceased WO1997037966A1 (fr) 1996-04-09 1997-04-08 Cytofectines quaternaires

Country Status (9)

Country Link
US (1) US5994317A (fr)
EP (1) EP0902780B1 (fr)
JP (1) JP4031045B2 (fr)
AT (1) ATE207874T1 (fr)
CA (1) CA2251169C (fr)
DE (1) DE69707870T2 (fr)
DK (1) DK0902780T3 (fr)
ES (1) ES2166540T3 (fr)
WO (1) WO1997037966A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214804B1 (en) 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6867195B1 (en) * 1989-03-21 2005-03-15 Vical Incorporated Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
AU6964191A (en) 1989-11-16 1991-06-13 Cornell Research Foundation Inc. Particle-mediated transformation of animal tissue cells
US6228844B1 (en) 1991-11-12 2001-05-08 Vical Incorporated Stimulating vascular growth by administration of DNA sequences encoding VEGF
US6706694B1 (en) 1990-03-21 2004-03-16 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
US7105574B1 (en) 1999-03-26 2006-09-12 Vical Incorporated Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
CA2641217A1 (fr) 1997-11-20 1999-06-03 Vical Incorporated Traitement du cancer au moyen de polynucleotides exprimant la cytokine et compositions prevues a cet effet
US6652864B1 (en) 1998-12-21 2003-11-25 Asilomar Pharmaceuticals, Inc. Compounds for intracellular delivery of therapeutic moieties to nerve cells
US20040120891A1 (en) 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
CA2365416C (fr) * 1999-03-26 2011-06-14 Vical Incorporated Compositions d'adjuvant et methodes permettant d'accentuer les reponses immunitaires a des vaccins a base de polynucleotides
AU5702699A (en) * 1999-09-03 2001-04-10 Procter & Gamble Company, The Cationic alkyl alkoxylate derivatives
WO2001080897A2 (fr) * 2000-04-21 2001-11-01 Vical Incorporated Compositions pour l'administration in vivo d'agents therapeutiques derives de polynucleotides et methodes associees
US20040204379A1 (en) * 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
KR100381512B1 (ko) 2000-09-21 2003-04-26 굿젠 주식회사 유전자 및 생물학적 활성 약물 전달용 양이온성 지질과이의 용도
WO2002047730A2 (fr) * 2000-11-06 2002-06-20 Asilomar Pharmaceuticals, Inc Composes pour administration intracellulaire de fractions therapeutiques a des cellules nerveuses
EP1399191A2 (fr) * 2001-06-07 2004-03-24 Celator Technologies Inc. Agent therapeutique de penetration cellulaire
JP4699025B2 (ja) 2002-05-15 2011-06-08 サッター・ウエスト・ベイ・ホスピタルズ 核酸様化合物の送達
US20070105799A1 (en) * 2002-09-10 2007-05-10 Vical Incorporated Codon-optimized polynucleotide-based vaccines against Bacillus anthracis infection
AU2003293196A1 (en) 2002-12-23 2004-07-29 Vical Incorporated Method for producing sterile polynucleotide based medicaments
CA2508279A1 (fr) * 2002-12-23 2004-07-22 Vical Incorporated Procede de lyophilisation de complexes d'acide nucleique/copolymere sequence/tensioactif cationique
US8080642B2 (en) * 2003-05-16 2011-12-20 Vical Incorporated Severe acute respiratory syndrome DNA compositions and methods of use
WO2006031689A2 (fr) 2004-09-13 2006-03-23 Genzyme Corporation Complexes multimeriques
US20060134221A1 (en) * 2004-12-03 2006-06-22 Vical Incorporated Methods for producing block copolymer/amphiphilic particles
WO2008106646A2 (fr) * 2007-03-01 2008-09-04 Introgen Therapeutics, Inc Procédés et formulations pour une thérapie génique topique
US9408914B2 (en) 2010-04-28 2016-08-09 Kyowa Hakko Kirin Co., Ltd. Cationic lipid
EP2567952A4 (fr) * 2010-04-28 2015-11-25 Kyowa Hakko Kirin Co Ltd Lipide cationique
JP2013095755A (ja) * 2011-11-02 2013-05-20 Kyowa Hakko Kirin Co Ltd カチオン性脂質
EP2858974B9 (fr) * 2012-06-08 2022-07-20 Nitto Denko Corporation Lipides pour des formulations d'administration d'agent thérapeutique
AU2016237148A1 (en) 2015-03-24 2017-11-23 Kyowa Hakko Kirin Co., Ltd. Nucleic acid-containing lipid nanoparticles
EP3746129A4 (fr) * 2018-02-01 2022-03-02 Trustees of Tufts College Nanocomplexes de type lipide et leurs utilisations
CA3105879A1 (fr) 2018-07-18 2020-01-23 Manzanita Pharmaceuticals, Inc. Conjugues pour administrer un agent anticancereux a des cellules nerveuses, methodes d'utilisation et leurs procedes de fabrication

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2368208A (en) * 1940-12-16 1945-01-30 Emulsol Corp Chemical compounds and method of preparing same
US3265719A (en) * 1959-12-28 1966-08-09 American Cyanamid Co Betaines
DE2651898A1 (de) * 1976-11-13 1978-05-18 Hoechst Ag Waescheweichspuelmittel
US5049386A (en) * 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
DE3618517A1 (de) * 1985-06-04 1986-12-04 Lion Corp., Tokio/Tokyo Emulgiermittel zur emulsionspolymerisation
US5068431A (en) * 1987-08-31 1991-11-26 Witco Corporation Methods of making new surface active compounds
US4864060A (en) * 1987-08-31 1989-09-05 Witco Corporation Surface active compounds, methods for making same and uses thereof
CA2001401A1 (fr) * 1988-10-25 1990-04-25 Claude Piantadosi Derives d'ether ou d'ester lipidique contenant une amine quaternaire et composes therapeutiques
JPH03181597A (ja) * 1989-12-12 1991-08-07 Bridgestone Corp 電気粘性流体
US5279833A (en) * 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5334761A (en) * 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
DE4241983C1 (de) * 1992-12-12 1994-03-24 Messer Griesheim Gmbh Schutzgas für das Lichtbogenschweißen von Aluminium
US5364324A (en) * 1992-12-14 1994-11-15 Boettiger Jr Walter W Exercise device
US5753613A (en) * 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells

Similar Documents

Publication Publication Date Title
WO1997037966B1 (fr) Cytofectines quaternaires
CA2237316A1 (fr) Lipides cationiques complexes
US6395713B1 (en) Compositions for the delivery of negatively charged molecules
US6656730B1 (en) Oligonucleotides conjugated to protein-binding drugs
US9107957B2 (en) Peptide-based in vivo siRNA delivery system
EP1709195B1 (fr) Formulations de transfection cellulaire de petits arn interferents, compositions correspondantes et procedes de production et d'utilisation
US20030073640A1 (en) Novel compositions for the delivery of negatively charged molecules
EP0777679B1 (fr) Apport d'acides nucleiques
Derrien et al. Muramyl dipeptide bound to poly-L-lysine substituted with mannose and gluconoyl residues as macrophage activators
US20020188101A1 (en) Conjugated peptide nucleic acids having enhanced cellular uptake
WO1995024222A1 (fr) Produits de conjugaison polymeres polycationiques cycliques-oligonucleotides et procedes de preparation
EP1316318A2 (fr) Méthode de transductions d'une protéine dans des cellules
CA2222586A1 (fr) Lipides thiocationiques, preparations pharmaceutiques et leurs modes d'utilisation
US20060142227A1 (en) Amphiphylic peptide-PNA conjugates for the delivery of PNA through the blood brain barrier
WO1993020090A1 (fr) Oligonucleotides a ions apparies et leurs procedes de preparation
JP2008519053A (ja) 小さい干渉ＲＮＡ（ｓｉＲＮＡ）のポリアミン共役体の合成及びそれによって形成された共役体
JPH09202799A5 (fr)
US7824910B2 (en) Method of transducing a protein into cells
TWI565476B (zh) 基於肽之活體內ｓｉＲＮＡ傳遞系統
EP1724254A2 (fr) Nouvelles compositions d'administration de molecules chargées negativement
HK1029578B (en) Novel compositions for the delivery of negatively charged molecules